MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. (Q53275543)
Jump to navigation
Jump to search
scientific article published on 22 May 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. |
scientific article published on 22 May 2017 |
Statements
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. (English)
1 reference
1 reference
Hope S Rugo
1 reference
Denise A Yardley
1 reference
Joyce O'Shaughnessy
1 reference
Sara M Tolaney
1 reference
Maura N Dickler
1 reference
Véronique Diéras
1 reference
Debra Patt
1 reference
Hans Wildiers
1 reference
Clifford A Hudis
1 reference
Esther Zamora
1 reference
Martin Frenzel
1 reference
Andrew Koustenis
1 reference
José Baselga
1 reference
22 May 2017
1 reference
23
1 reference
17
1 reference
5218-5224
1 reference
1 reference
1 reference
Identifiers
1 reference